Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) Operating Expenses (2016 - 2025)

Perspective Therapeutics' Operating Expenses history spans 15 years, with the latest figure at $45.2 million for Q4 2024.

  • For Q4 2024, Operating Expenses rose 321.3% year-over-year to $45.2 million; the TTM value through Sep 2025 reached $45.2 million, down 21.84%, while the annual FY2024 figure was $92.3 million, 117.91% up from the prior year.
  • Operating Expenses for Q4 2024 was $45.2 million at Perspective Therapeutics, up from $19.0 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $45.2 million in Q4 2024 and bottomed at -$4.3 million in Q4 2021.
  • The 5-year median for Operating Expenses is $4.0 million (2021), against an average of $8.1 million.
  • The largest annual shift saw Operating Expenses tumbled 311.42% in 2021 before it soared 321.3% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $2.0 million in 2020, then crashed by 311.42% to -$4.3 million in 2021, then soared by 230.33% to $5.6 million in 2022, then surged by 90.94% to $10.7 million in 2023, then skyrocketed by 321.3% to $45.2 million in 2024.
  • Per Business Quant, the three most recent readings for CATX's Operating Expenses are $45.2 million (Q4 2024), $19.0 million (Q3 2024), and $14.8 million (Q2 2024).